Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 96.43% | 84.95% | 149.35% | 17.26% | 20.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.43% | 84.95% | 149.35% | 17.26% | 20.20% |
| Cost of Revenue | 197.18% | 160.39% | 132.99% | 108.17% | 7.68% |
| Gross Profit | 82.75% | 69.13% | 152.73% | 6.70% | 22.13% |
| SG&A Expenses | 34.42% | 10.17% | 45.74% | 30.16% | 13.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.97% | 38.23% | 52.48% | 29.23% | 7.13% |
| Operating Income | 1,386.07% | 225.26% | 578.49% | -133.32% | 141.62% |
| Income Before Tax | 9,460.35% | 183.08% | 319.92% | -216.63% | 96.28% |
| Income Tax Expenses | -1.39% | 77.06% | -516.75% | 440.35% | 576.45% |
| Earnings from Continuing Operations | 1,228.66% | 322.56% | 325.05% | -292.43% | 72.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,228.66% | 322.56% | 325.05% | -292.43% | 72.32% |
| EBIT | 1,386.07% | 225.26% | 578.49% | -133.32% | 141.62% |
| EBITDA | 768.76% | 259.60% | 706.75% | -103.54% | 208.57% |
| EPS Basic | 1,201.71% | 317.33% | 320.17% | -280.65% | 73.08% |
| Normalized Basic EPS | 15,429.41% | 161.46% | 354.06% | -236.85% | 97.84% |
| EPS Diluted | 1,172.00% | 310.82% | 311.49% | -280.65% | 73.08% |
| Normalized Diluted EPS | 14,838.24% | 159.64% | 343.15% | -236.85% | 97.84% |
| Average Basic Shares Outstanding | 2.48% | 2.41% | 2.22% | 3.07% | 2.80% |
| Average Diluted Shares Outstanding | 6.59% | 5.55% | 6.81% | 3.07% | 2.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |